{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Very good partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Minor response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Progressive disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"Descriptive statistics will be used for baseline characteristics, and responses to treatment.","groups":[{"description":"Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who fail to achieve at least 25% M-protein reduction for Waldenstrom's macroglobulinemia or partial response for marginal zone lymphoma after 2 courses of carfilzomib will continue to receive carfolzomib for 4 more courses. In addition, they will also receive rituximab IV weekly on days 1, 8, 15, and 22 of course 3 and then monthly on day 1 of courses 4-6 in the absence of disease progression or unacceptable toxicity.\n\nCarfilzomib: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRituximab: Given IV","id":"OG000","title":"Treatment (Carfilzomib, Rituximab)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who were evaluated after cycle 2 day 15 and prior to cycle 3 day 1.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Overall Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}